Stryker (NYSE:SYK) Given New $390.00 Price Target at Evercore ISI

Stryker (NYSE:SYK - Free Report) had its price objective decreased by Evercore ISI from $400.00 to $390.00 in a research note released on Friday morning,Benzinga reports. Evercore ISI currently has an outperform rating on the medical technology company's stock.

Other analysts also recently issued reports about the stock. Canaccord Genuity Group raised their price objective on shares of Stryker from $420.00 to $435.00 and gave the company a "buy" rating in a research report on Wednesday, January 29th. BTIG Research set a $403.00 price target on Stryker and gave the company a "buy" rating in a report on Monday, April 14th. Barclays boosted their target price on Stryker from $418.00 to $443.00 and gave the company an "overweight" rating in a research report on Monday, February 10th. Argus set a $450.00 price target on Stryker in a research report on Monday, February 3rd. Finally, Stifel Nicolaus increased their target price on shares of Stryker from $400.00 to $440.00 and gave the stock a "buy" rating in a report on Wednesday, January 29th. Five analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $425.84.

Stryker Trading Up 1.2 %

Shares of SYK traded up $4.49 during trading hours on Friday, reaching $382.01. 479,963 shares of the company traded hands, compared to its average volume of 1,355,064. The company's fifty day moving average price is $365.95 and its two-hundred day moving average price is $374.03. The company has a quick ratio of 1.32, a current ratio of 1.95 and a debt-to-equity ratio of 0.59. The company has a market capitalization of $145.81 billion, a price-to-earnings ratio of 49.18, a price-to-earnings-growth ratio of 2.93 and a beta of 0.93. Stryker has a 12 month low of $314.93 and a 12 month high of $406.19.

Stryker (NYSE:SYK - Get Free Report) last announced its earnings results on Thursday, May 1st. The medical technology company reported $2.84 EPS for the quarter, beating analysts' consensus estimates of $2.73 by $0.11. Stryker had a net margin of 13.25% and a return on equity of 23.58%. The firm had revenue of $5.87 billion for the quarter, compared to analysts' expectations of $5.68 billion. During the same quarter in the previous year, the business posted $2.50 EPS. The company's quarterly revenue was up 11.9% on a year-over-year basis. Equities research analysts predict that Stryker will post 13.47 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Stryker news, Director Allan C. Golston sold 2,458 shares of the stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $383.07, for a total transaction of $941,586.06. Following the transaction, the director now owns 14,895 shares of the company's stock, valued at $5,705,827.65. This trade represents a 14.16 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 5.90% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Stryker

Several institutional investors have recently bought and sold shares of SYK. Kohmann Bosshard Financial Services LLC acquired a new position in shares of Stryker during the fourth quarter worth about $25,000. Capital A Wealth Management LLC acquired a new position in Stryker during the 4th quarter worth approximately $26,000. Rakuten Securities Inc. boosted its holdings in Stryker by 618.2% in the 4th quarter. Rakuten Securities Inc. now owns 79 shares of the medical technology company's stock worth $28,000 after acquiring an additional 68 shares during the period. Centricity Wealth Management LLC acquired a new stake in Stryker in the fourth quarter valued at approximately $30,000. Finally, Goodman Advisory Group LLC purchased a new stake in shares of Stryker during the first quarter valued at approximately $32,000. 77.09% of the stock is currently owned by hedge funds and other institutional investors.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.